Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.

The American journal of medicine - 1 Apr 2017

Tzoran Inna, Papadakis Manolis, Brenner Benjamin, Fidalgo Ángeles, Rivas Agustina, Wells Philip S, Gavín Olga, Adarraga María Dolores, Moustafa Farès, Monreal Manuel

Abstract excerpt

BACKGROUND: Individuals with factor V Leiden or prothrombin G20210A mutations are at a higher risk to develop venous thromboembolism. However, the influence of these polymorphisms on patient outcome during anticoagulant therapy has not been consistently explored. METHODS: We used the Registro Informatizado de Enfermedad TromboEmbólica database to compare rates of venous thromboembolism recurrence and bleeding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activated Protein C Resistance
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor V

Share to Hemorrhage

Share to Heterozygote

Share to Prothrombin

Share to Treatment Outcome

Share to Venous Thromboembolism

Source

Identifiers

PMID: 27986523
DOI: 10.1016/j.amjmed.2016.11.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.PMID 27986523Read ↗

The Association of Prothrombin Gene G20210A Mutation with Recurrent Venous Thromboembolism: Evidence from a Meta-Analysis.Semantic proximity Read ↗

Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia.Semantic proximity Read ↗

Genetic Risk Profiling Associated with Recurrent Unprovoked Venous Thromboembolism.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.Semantic proximity Read ↗

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.Semantic proximity Read ↗

The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.Semantic proximity Read ↗

G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.Semantic proximity Read ↗

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.Semantic proximity Read ↗

FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population.Semantic proximity Read ↗

Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relativesSemantic proximity Read ↗

Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.Semantic proximity Read ↗

Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.